Every Day Matters
Delivering on our vision is a team effort and together we’re undaunted by the challenge. We’re advancing a pipeline of novel, engineered TIL cell therapies to deliver potentially safer, more effective treatments for more patients with solid tumors. Our lead clinical program, amsoki-cel (OBX-115), is now treating patients with metastatic melanoma and non-small cell lung cancer.
Through partnerships we apply our cytoDRiVE® platform technology to enable discovery of novel therapies with the potential to expand our impact and reach a wider range of patients.
Our Culture
We know that patients are waiting, and we’re fiercely committed to delivering transformative therapies as fast as we responsibly can. We act with integrity and challenge ourselves and each other to bring our best every day.
We’re constantly questioning our assumptions, expanding our knowledge, generating and testing new ideas and approaches. Our curiosity drives our innovation.
We don’t believe in silos or hierarchies. We share ideas, strive and learn together, trust each other, and appreciate the value that every member of our team contributes.
We believe that healthy relationships and high performing teams develop when we can be our whole selves. We make time to connect, have fun, and get to know each other’s stories and interests.
Like the diversity of obsidian sources, our team brings varied backgrounds, identities, and experiences. Our collective knowledge, intellect, and energy is our greatest source of strength.
Testimonials
“One of the main reasons I joined Obsidian still rings true – there is a lot of room to take on important responsibilities and learn new things that will help us build our program and see it succeed.”
–Lauren McLaughlin, Associate Director, Clinical Operations
“There is such camaraderie and cross-functional collaboration between the Analytical and Process Development teams which is fantastic! And within Analytical Development everyone is helpful, supportive, and critical of each other’s work in a caring way that helps us to learn and drive better results.”
–Amanda Logan, Senior Associate Scientist, Analytical Development
“We have a real platform that can make a real difference in people’s lives, allowing us to dose in immuno-oncology what we couldn’t otherwise because it was too toxic.”
–Dhruv Sethi, Senior Director, Discovery & DRD Technologies
“We’re very patient centric and focused on how our work can translate to patient response, which is very inspiring to me. We’re at the forefront of TIL therapy, the challenges make it interesting and there is synergy between research and tech ops when we work hand in hand.”
–Zheng Ao, Associate Director, Cell Therapy
“The #1 reason I joined was the science. I thought it was an interesting take on cell therapy, I liked the evidence that TILs work, and I can see a benefit for the patients.”
–Nicole Hsu, VP, Regulatory Affairs
